No 03 2023

SwedenBIO recently released our new Swedish Drug Discovery and Development Pipeline Report 2026 at NLSDays in Gothenburg. This fourteenth edition once again shows that Swedish drug development remains on a stable trajectory. Fluctuations in the number of drug-developing companies and in the number or type of projects are minimal compared to our report from three years ago.

Pfizer has entered into an exclusive global collaboration and license agreement with YaoPharma, a subsidiary of Shanghai Fosun Pharmaceutical for the development, manufacturing and commercialization of YP05002, a small molecule glucagon-like peptide 1 (GLP-1) receptor agonist currently in Phase 1 development for chronic weight management.

CellaVision has announced that its new CellaVision Bone Marrow Aspirate (BMA) Application has received CE marking approval as a Class C product under the European Union In Vitro Diagnostic Regulation (EU IVDR).

BioArctic’s partner Eisai has announced that Leqembi (lecanemab), has been included in the “Commercial Insurance Innovative Drug List”, recently introduced by the National Healthcare Security Administration (NHSA) of China.

The US Food and Drug Administration (FDA) has approved the company’s Investigational New Drug (IND) application for TCP-25, a novel topical immunomodulatory peptide being developed for the treatment of Epidermolysis Bullosa (EB).

Niels Buch Leander has been appointed new Chief Digital Officer (CDO) and Executive Vice President (EVP) Denmark.

Cinclus Pharma Holding's drug linaprazan glurate has been included in China’s 2025 National Reimbursement Drug List (NRDL) for the treatment of gastroesophageal reflux disease (GERD).